|
|
|
|
| LEADER |
01144naa a2200289 i 4500 |
| 001 |
NSK01001155984 |
| 003 |
HR-ZaNSK |
| 005 |
20221202154622.0 |
| 007 |
ta |
| 008 |
190410s2020 ci | |0|| ||eng |
| 035 |
|
|
|a (HR-ZaNSK)001155984
|
| 040 |
|
|
|a HR-ZaNSK
|b hrv
|c HR-ZaNSK
|e ppiak
|
| 042 |
|
|
|a croatica
|
| 044 |
|
|
|a ci
|c hr
|
| 080 |
1 |
|
|a 577
|2 2011
|
| 080 |
1 |
|
|a 615
|2 2011
|
| 100 |
1 |
|
|a Saha, Chandni
|4 aut
|9 HR-ZaNSK
|
| 245 |
1 |
0 |
|a Development and validation of a UPLC-MS method for determination of atazanavir sulfate by the "analytical quality by design" approach /
|c Chandni Saha, N. Vishal Gupta, R. S. Chandan.
|
| 300 |
|
|
|b Graf. prikazi.
|
| 504 |
|
|
|a Bibliografija: 37 jed.
|
| 653 |
|
0 |
|a Antiretrovirusni lijekovi
|a Inhibitori proteaze
|a Atazanavir sulfat
|a Analitičke metode
|a Tekućinska kromatografija
|a Optimizacija
|a Procjena rizika
|
| 700 |
1 |
|
|a Gupta, N. Vishal
|4 aut
|
| 700 |
1 |
|
|a Chandan, R. S.
|4 aut
|9 HR-ZaNSK
|
| 773 |
0 |
|
|t Acta pharmaceutica (Zagreb)
|x 1330-0075
|g 70 (2020), 1 ; str. 17-33
|w nsk.(HR-ZaNSK)000054908
|
| 981 |
|
|
|b B07/20
|
| 998 |
|
|
|b milo2212
|
| 856 |
4 |
1 |
|u https://hrcak.srce.hr/220833
|y Elektronička verzija članka
|